Pancreatic adenocarcinoma

The actual 5-year survivors

Cristina R. Ferrone, Murray F. Brennan, Mithat Gonen, Daniel G. Coit, Yuman Fong, Sun M. Chung, Laura Tang, David Klimstra, Peter J. Allen

Research output: Contribution to journalArticle

161 Citations (Scopus)

Abstract

Most reports of patients undergoing resection for pancreatic adenocarcinoma report estimated (actuarial) 5-year survival rates. Actual 5-year survival is rarely described, and factors associated with long-term survival are not well described. Review of a prospectively maintained database identified 618 patients who underwent resection for pancreatic adenocarcinoma between 1/1983-1/2001. Patient, tumor, and treatment-related variables were assessed for their association with 5-year survival. There were 75 patients who survived >5 years after resection (75 out of 618, 12%), and 18 patients who survived >10 years (18 out of 352, 5%). Patient age, gender, and tumor location were not associated with 5-year survival, whereas early American Joint Committee on Cancer (AJCC) stage (p∈<∈0.001) and negative margins (p∈=∈0.001) were associated with 5-year survival. Patients with stage IA disease had an actual 5 year survival of 26%. Median follow-up was 108 months. Recurrent disease developed in 38 patients (51%) and all died from disease. Adjuvant therapy was received by 21% (16 out of 75), and tumors were moderately differentiated in 58% (42 out of 75) and had a median size of 2.8 cm (0.8-13 cm). Actual 5-year survival after resection of pancreatic adenocarcinoma was 12%. AJCC stage and negative margins were the only significant predictors of long-term survival. Early detection and intervention for patients with pancreatic cancer is crucial.

Original languageEnglish (US)
Pages (from-to)701-706
Number of pages6
JournalJournal of Gastrointestinal Surgery
Volume12
Issue number4
DOIs
StatePublished - Apr 2008
Externally publishedYes

Fingerprint

Survivors
Adenocarcinoma
Survival
Neoplasms
Pancreatic Neoplasms
Survival Rate
Databases
Therapeutics

Keywords

  • 5-Year survivors
  • Pancreatic adenocarcinoma

ASJC Scopus subject areas

  • Surgery

Cite this

Ferrone, C. R., Brennan, M. F., Gonen, M., Coit, D. G., Fong, Y., Chung, S. M., ... Allen, P. J. (2008). Pancreatic adenocarcinoma: The actual 5-year survivors. Journal of Gastrointestinal Surgery, 12(4), 701-706. https://doi.org/10.1007/s11605-007-0384-8

Pancreatic adenocarcinoma : The actual 5-year survivors. / Ferrone, Cristina R.; Brennan, Murray F.; Gonen, Mithat; Coit, Daniel G.; Fong, Yuman; Chung, Sun M.; Tang, Laura; Klimstra, David; Allen, Peter J.

In: Journal of Gastrointestinal Surgery, Vol. 12, No. 4, 04.2008, p. 701-706.

Research output: Contribution to journalArticle

Ferrone, CR, Brennan, MF, Gonen, M, Coit, DG, Fong, Y, Chung, SM, Tang, L, Klimstra, D & Allen, PJ 2008, 'Pancreatic adenocarcinoma: The actual 5-year survivors', Journal of Gastrointestinal Surgery, vol. 12, no. 4, pp. 701-706. https://doi.org/10.1007/s11605-007-0384-8
Ferrone, Cristina R. ; Brennan, Murray F. ; Gonen, Mithat ; Coit, Daniel G. ; Fong, Yuman ; Chung, Sun M. ; Tang, Laura ; Klimstra, David ; Allen, Peter J. / Pancreatic adenocarcinoma : The actual 5-year survivors. In: Journal of Gastrointestinal Surgery. 2008 ; Vol. 12, No. 4. pp. 701-706.
@article{6c95f44d77a34828a233e7fef2e9be40,
title = "Pancreatic adenocarcinoma: The actual 5-year survivors",
abstract = "Most reports of patients undergoing resection for pancreatic adenocarcinoma report estimated (actuarial) 5-year survival rates. Actual 5-year survival is rarely described, and factors associated with long-term survival are not well described. Review of a prospectively maintained database identified 618 patients who underwent resection for pancreatic adenocarcinoma between 1/1983-1/2001. Patient, tumor, and treatment-related variables were assessed for their association with 5-year survival. There were 75 patients who survived >5 years after resection (75 out of 618, 12{\%}), and 18 patients who survived >10 years (18 out of 352, 5{\%}). Patient age, gender, and tumor location were not associated with 5-year survival, whereas early American Joint Committee on Cancer (AJCC) stage (p∈<∈0.001) and negative margins (p∈=∈0.001) were associated with 5-year survival. Patients with stage IA disease had an actual 5 year survival of 26{\%}. Median follow-up was 108 months. Recurrent disease developed in 38 patients (51{\%}) and all died from disease. Adjuvant therapy was received by 21{\%} (16 out of 75), and tumors were moderately differentiated in 58{\%} (42 out of 75) and had a median size of 2.8 cm (0.8-13 cm). Actual 5-year survival after resection of pancreatic adenocarcinoma was 12{\%}. AJCC stage and negative margins were the only significant predictors of long-term survival. Early detection and intervention for patients with pancreatic cancer is crucial.",
keywords = "5-Year survivors, Pancreatic adenocarcinoma",
author = "Ferrone, {Cristina R.} and Brennan, {Murray F.} and Mithat Gonen and Coit, {Daniel G.} and Yuman Fong and Chung, {Sun M.} and Laura Tang and David Klimstra and Allen, {Peter J.}",
year = "2008",
month = "4",
doi = "10.1007/s11605-007-0384-8",
language = "English (US)",
volume = "12",
pages = "701--706",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Pancreatic adenocarcinoma

T2 - The actual 5-year survivors

AU - Ferrone, Cristina R.

AU - Brennan, Murray F.

AU - Gonen, Mithat

AU - Coit, Daniel G.

AU - Fong, Yuman

AU - Chung, Sun M.

AU - Tang, Laura

AU - Klimstra, David

AU - Allen, Peter J.

PY - 2008/4

Y1 - 2008/4

N2 - Most reports of patients undergoing resection for pancreatic adenocarcinoma report estimated (actuarial) 5-year survival rates. Actual 5-year survival is rarely described, and factors associated with long-term survival are not well described. Review of a prospectively maintained database identified 618 patients who underwent resection for pancreatic adenocarcinoma between 1/1983-1/2001. Patient, tumor, and treatment-related variables were assessed for their association with 5-year survival. There were 75 patients who survived >5 years after resection (75 out of 618, 12%), and 18 patients who survived >10 years (18 out of 352, 5%). Patient age, gender, and tumor location were not associated with 5-year survival, whereas early American Joint Committee on Cancer (AJCC) stage (p∈<∈0.001) and negative margins (p∈=∈0.001) were associated with 5-year survival. Patients with stage IA disease had an actual 5 year survival of 26%. Median follow-up was 108 months. Recurrent disease developed in 38 patients (51%) and all died from disease. Adjuvant therapy was received by 21% (16 out of 75), and tumors were moderately differentiated in 58% (42 out of 75) and had a median size of 2.8 cm (0.8-13 cm). Actual 5-year survival after resection of pancreatic adenocarcinoma was 12%. AJCC stage and negative margins were the only significant predictors of long-term survival. Early detection and intervention for patients with pancreatic cancer is crucial.

AB - Most reports of patients undergoing resection for pancreatic adenocarcinoma report estimated (actuarial) 5-year survival rates. Actual 5-year survival is rarely described, and factors associated with long-term survival are not well described. Review of a prospectively maintained database identified 618 patients who underwent resection for pancreatic adenocarcinoma between 1/1983-1/2001. Patient, tumor, and treatment-related variables were assessed for their association with 5-year survival. There were 75 patients who survived >5 years after resection (75 out of 618, 12%), and 18 patients who survived >10 years (18 out of 352, 5%). Patient age, gender, and tumor location were not associated with 5-year survival, whereas early American Joint Committee on Cancer (AJCC) stage (p∈<∈0.001) and negative margins (p∈=∈0.001) were associated with 5-year survival. Patients with stage IA disease had an actual 5 year survival of 26%. Median follow-up was 108 months. Recurrent disease developed in 38 patients (51%) and all died from disease. Adjuvant therapy was received by 21% (16 out of 75), and tumors were moderately differentiated in 58% (42 out of 75) and had a median size of 2.8 cm (0.8-13 cm). Actual 5-year survival after resection of pancreatic adenocarcinoma was 12%. AJCC stage and negative margins were the only significant predictors of long-term survival. Early detection and intervention for patients with pancreatic cancer is crucial.

KW - 5-Year survivors

KW - Pancreatic adenocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=40849136668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40849136668&partnerID=8YFLogxK

U2 - 10.1007/s11605-007-0384-8

DO - 10.1007/s11605-007-0384-8

M3 - Article

VL - 12

SP - 701

EP - 706

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 4

ER -